ZIOPHARM Oncology, Inc. — 2015 Form 10-K
Filing identity: The supplied filing is for ZIOPHARM Oncology, Inc., not Alaunos Therapeutics, Inc. It covers the fiscal year ended December 31, 2015; financial amounts below are U.S. dollars.
Business context and reporting period
ZIOPHARM was a development-stage biopharmaceutical company focused on cancer therapies, particularly synthetic immuno-oncology and engineered cell therapies. Its lead gene-therapy candidate was Ad-RTS-IL-12 plus veledimex. The company reported no product sales; collaboration and license arrangements generated its revenue.
Programs included clinical studies of Ad-RTS-IL-12 plus veledimex in brain and breast cancer, CAR-T studies conducted with MD Anderson, and earlier-stage NK-cell, TCR and graft-versus-host disease programs. No product candidate had received marketing approval.
Financial performance and position
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Collaboration revenue | $4.3 million | $1.4 million |
| Research and development expense | $106.8 million | $32.7 million |
| General and administrative expense | $17.6 million | $12.2 million |
| Operating loss | $120.1 million | $43.5 million |
| Net loss | $120.1 million | $31.8 million |
| Basic and diluted loss per share | $0.96 | $0.31 |
| Cash and cash equivalents at year-end | $140.7 million | $42.8 million |
| Working capital at year-end | $134.4 million | $33.3 million |
- Revenue increased 216%, primarily from $3.2 million recognized under the Ares Trading collaboration and $1.1 million from Solasia and $0.05 million from Predictive Therapeutics.
- R&D expense rose 226%, including a $67.3 million noncash charge for MD Anderson-licensed in-process research and development and a $10.0 million charge for the Intrexon GvHD collaboration. Management also cited higher CAR-T program spending, partly offset by lower discovery, nonclinical and personnel costs.
- Operating cash flow was a use of just $10,000, compared with $36.7 million used in 2014. This reported figure was affected by noncash expenses and a $53.4 million increase in deferred revenue; it should not be read as the company’s recurring cash burn.
- Cash increased by $97.9 million, mainly from $94.3 million net proceeds from a February 2015 public stock offering and $4.6 million from option exercises. The company also received $57.5 million from Intrexon under the Ares agreement; it recorded the payment as deferred revenue and recognized it over the estimated nine-year performance period.
- Total liabilities were $66.4 million, including $54.8 million of deferred revenue; the filing reports no outstanding warrants at year-end and does not identify funded debt. Cash runway was estimated to extend into the fourth quarter of 2017, but management warned that costs and timing could vary and that no additional capital was committed.
Profit margins are not meaningful for this pre-revenue development company. No product revenue or profitability was reported.
Material changes versus the prior comparable period
- Net loss widened to $120.1 million from $31.8 million. The 2014 result included an $11.7 million warrant fair-value gain; no such gain was recorded in 2015 because the warrants had expired.
- R&D spending increased substantially following the MD Anderson license and expansion of CAR-T research. The MD Anderson license consideration included 11.7 million ZIOPHARM shares, valued at $67.3 million and expensed as in-process R&D.
- Year-end cash rose from $42.8 million to $140.7 million, supported by the equity offering and collaboration funding. Shares outstanding increased from 104.5 million to 131.7 million during 2015.
- In September 2015 the company entered a GvHD collaboration with Intrexon, paid a $10 million technology access fee and agreed to reimburse research costs and share product profits equally, subject to contract terms.
Outlook, risks, contingencies and unusual items
- Management expected 2016 updates from the GBM and breast cancer studies; it planned to advance CAR-T, myeloid malignancy, off-the-shelf NK-cell and GvHD programs. These were expectations, not guaranteed milestones. The filing also reports a February 2016 GBM dosing update after year-end.
- The company committed to fund MD Anderson research for three years at $15 million to $20 million annually. It had paid $11.25 million during 2015, with $10.3 million remaining in a current asset at year-end after amounts used by MD Anderson.
- The Ares collaboration offered potential development and commercial milestone payments of up to $413 million per product candidate, plus technical milestones and royalties. These are contingent and not assured; ZIOPHARM’s share is governed by its agreement with Intrexon.
- Principal risks include clinical and regulatory failure, safety and manufacturing challenges in gene and cell therapies, competition, dependence on Intrexon and MD Anderson licenses, intellectual-property disputes, reimbursement and adoption uncertainty, and the need for future financing. Equity financing could dilute shareholders.
- Contractual obligations totaled $39.3 million as presented, including operating leases and royalty/license fees; the filing notes that the table excludes additional MD Anderson research funding obligations of $15 million in the next year and $18.75 million in years two and three.
- Management reported no legal proceedings expected to materially affect financial position, results or cash flows. The auditor gave an unqualified opinion on the financial statements and internal controls; management also concluded disclosure controls and internal control over financial reporting were effective as of year-end.
Important facts for investors to verify
- Confirm the issuer and ticker: this filing identifies ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), rather than Alaunos Therapeutics, Inc.
- Review the audited financial statements and cash-flow reconciliation, especially how noncash license charges and deferred collaboration revenue affect reported operating cash flow.
- Track actual clinical enrollment, safety and efficacy results, regulatory feedback, and whether stated 2016 development milestones were achieved.
- Assess cash use against the stated runway and the MD Anderson funding commitment; verify the timing and terms of any future financing.
- Check the detailed Intrexon, MD Anderson and Ares agreements for cost-sharing, termination, licensing, milestone and royalty provisions, and consider potential share dilution.